Molina J-M, et al. Doravirine (DOR) versus ritonavir-boosted darunavir (DRV+r): 96-week results of the randomized, double-blind, phase 3 DRIVE-FORWARD Noninferiority trial. AIDS 2018.
MS in tijden van COVID-19
mei 2021 | Multipele Sclerose, Vaccinatie, Virale infecties